ATC Group: D05AX Other antipsoriatics for topical use

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D05AX in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D05 Antipsoriatics
3 D05A Antipsoriatics for topical use
4 D05AX Other antipsoriatics for topical use

Group D05AX contents

Code Title
D05AX01 Fumaric acid
D05AX02 Calcipotriol
D05AX03 Calcitriol
D05AX04 Tacalcitol
D05AX05 Tazarotene
D05AX06
D05AX07
D05AX52 Calcipotriol, combinations
D05AX55

Active ingredients in D05AX

Active Ingredient

Calcipotriol is a derivative of vitamin D for topical use on psoriasis. It probably works by suppressing keratinization. Advantage of substance or absence of odor and non-coloring of clothing.

Calcitriol is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In physiological amounts it augments the intestinal absorption of calcium and phosphate and plays a significant part in the regulation of bone mineralisation.

Roflumilast is a PDE4 inhibitor, a non-steroid, anti-inflammatory active substance designed to target both the systemic and pulmonary inflammation associated with COPD.

Tacalcitol is a vitamin D3 derivative, which inhibits keratinocyte hyper-proliferation and induces differentiation of these cells. The normalisation of these mechanisms is the basis for the efficacy in the treatment of psoriasis.

Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which tapinarof cream exerts its therapeutic action in psoriasis patients are unknown.

Tazarotene, a member of the acetylenic class of retinoids, is a prodrug which is converted to its active free form, tazarotenic acid, by de-esterification in the skin area. Tazarotenic acid is the only known metabolite of tazarotene to have retinoid activity.

Related product monographs

Document Type Information Source  
 CURATODERM Ointment MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DAIVOBET Gel MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DAIVONEX Ointment MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)
 DOVOBET Gel MPI, EU: SmPC Health Products Regulatory Authority (IE)
 Dovonex Ointment MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ENSTILAR Foam MPI, US: SPL/PLR FDA, National Drug Code (US)
 SILKIS Ointment MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 TAZORAC Cream MPI, US: SPL/PLR FDA, National Drug Code (US)
 TAZORAC Gel MPI, US: SPL/PLR FDA, National Drug Code (US)
 VTAMA Cream MPI, US: SPL/PLR FDA, National Drug Code (US)
 ZORAC Gel MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)